Search alternatives:
ns decrease » _ decrease (Expand Search), use decreased (Expand Search), ash decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
09 a » 19 a (Expand Search), 09 1 (Expand Search), 09 0 (Expand Search)
ns decrease » _ decrease (Expand Search), use decreased (Expand Search), ash decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
09 a » 19 a (Expand Search), 09 1 (Expand Search), 09 0 (Expand Search)
-
221
-
222
-
223
-
224
Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF
Published 2023“…Background<p>We estimated the association between the level of restriction in nine different fields of activity and SARS-CoV-2 transmissibility in Spain, from 15 September 2020 to 9 May 2021.…”
-
225
-
226
-
227
Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oest...
Published 2017“…</p> <p><b>Objective:</b> We hypothesized that nicotine would ameliorate insulin resistance (IR) that is accompanied by decreased cardiac glycogen synthase kinase-3 (GSK-3) and plasminogen activator inhibitor-1 (PAI-1).…”
-
228
-
229
-
230
-
231
-
232
-
233
Vectorized siRNA TMPRSS2-ERG IV-SQ impaired tumour growth and restored differentiation <i>in vivo</i>.
Published 2015“…<p><b>a.</b> SCID mice (n = 5/group) bearing VCaP tumour xenografts were injected intravenously either with NaCl 0.9%, non-vectorized siRNA TMPRSS2-ERG IV, NPs siRNA control-SQ or NPs siRNA TMPRSS2-ERG IV-SQ twice per week during 6 weeks (1.8 mg/kg/mouse cumulative dose). …”
-
234
-
235
-
236
-
237
-
238
-
239
-
240